A Study to Evaluate the Efficacy and Safety of Long-term Administration of K-CAB Tab./K-CAB ODT(Tegoprazan) 25 mg as Maintenance Therapy Following the Treatment of GERD

This study aims to assess heartburn and acid regurgitation symptoms during long-term administration of K-CAB Tab/K-CAB ODT(Tegoprazan) 25 mg in patients with GERD in routine clinical practice. The study will also evaluate safety information, including important potential risks.

Inclusion Criteria: 1. Aged 19 years or older on the date written informed consent is obtained 2. Determined by the investigator, based on medical judgment, to receive K-CAB Tab/K-CAB ODT 25 mg 3. Scheduled to receive K-CAB Tab/K-CAB ODT 25 mg, as maintenance therapy following treatment for gastroesophageal reflux disease (GERD) 4. Voluntarily agrees to participate in the study and provides written informed consent Exclusion Criteria: 1. Individuals who meet any of the contraindications listed under "Contraindications" in the "Precautions for Use" section of the approved prescribing information for K-CAB Tab/K-CAB ODT 25 mg 2. Individuals whom the investigator considers unsuitable for participation in this study for any other reason